The tech equity org hosted its second annual Innovation Weekend, concluding with an awards event that honored members of the Philly tech community in seven categories.
Despite struggles to consistently fund and work on the startup, the founder and researcher said she sticks with it because of the impact it could have for people who need donor tissue.
Imvax abstracts accepted for presentation at AACR 2021 annual meeting
News provided by
Share this article
Share this article
PHILADELPHIA, March 3, 2021 /PRNewswire/ Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma (GBM) and other cancers, announced today that its prior and upcoming GBM immunotherapy clinical studies and preclinical studies will be presented as e-posters at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting 2021, April 10-15 and May 17-21.
Details of the abstracts and e-poster presentations are as follows:
Title: ImmuneSense: A randomized, double-blind, placebo-controlled phase 2b study of IGV-001, a novel combination autologous cell immunotherapy, in patients with newly diagnosed glioblastoma multiforme